Gain Therapeutics Stock (NASDAQ:GANX)

Forecast Ownership Financials Chart

Previous Close

$1.64

52W Range

$1.41 - $4.34

50D Avg

$1.85

200D Avg

$2.20

Market Cap

$72.09M

Avg Vol (3M)

$657.96K

Beta

0.16

Div Yield

GANX Company Profile

Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 19, 2021

Website

GANX Performance

GANX Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	$55.18K
Operating Income	$-18.71M	$-20.35M	$-22.25M
Net Income	$-20.16M	$-20.41M	$-22.27M
EBITDA	$-18.71M	$-20.27M	$-22.17M
Basic EPS	$-0.61	$-0.89	$-1.71
Diluted EPS	$-0.61	$-0.89	$-1.71

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
OSTX	OS Therapies Incorporated
LITS	Lite Strategy, Inc.
TCRX	TScan Therapeutics, Inc.
CRVO	CervoMed Inc.
NRXP	NRx Pharmaceuticals, Inc.
ADAG	Adagene Inc.
FBIO	Fortress Biotech, Inc.
NTRB	Nutriband Inc.
XBIT	XBiotech Inc.
ACET	Adicet Bio, Inc.